Larissa Alexsandra Felix

Mrs. Larissa Alexsandra Felix

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
Verified
Journal Article
Open access
PDF file
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
BSBruna Christina Fernandes Soares
Bruna Christina Fernandes Soares
GSGonzalo Suárez
Gonzalo Suárez
HBHumberto de Mello Brandão
Humberto de Mello Brandão
MFMARCOS FERRANTE
MARCOS FERRANTE
This study aims to determine therapeutic protocols of intramuscular sodium cloxacillin (IM) in goats with potential antibacterial effects against Staphylococcus spp. We constructed a pharmacokinetic (PK) model of IM, followed by a pharmacokinetic/pharmacodynamic integration (PK/PD). Simulations of different therapeutic protocols were then performed, with the doses ranging from 30 to100 mg/kg every 8, 12, or 24 hours. We calculated the probability to target attainment (PTA) of reach protocol's therapeutic according to the minimum inhibitory concentration (MIC) range of 0.06 to 4 μg/mL. The PK/PD index (PDT) used was "time above the MIC for 40% of the time" (T>MIC ≥40%). Protocols with single administration per day were incapable of achieving PTA ≥ 90% for any of the estimated MICs. However, by decreasing the administration interval, the PTA was increased. Thus, from the dose of 50 mg/kg every 12 hours, a PTA≥ 90% for MICs ≤ 0.5 μg/mL was achieved, while the 30 mg/kg dose every 8 hours was able to achieve a PTA≥ 90% for MICs of 2 μg/mL. The results suggest using 30 mg/kg dose every 8 hours in clinical studies of agents with MICs ≤ 2μg/mL; Nevertheless, the practitioner should adjust the dose in severe patients.

30 June 2023 in Journal of Applied Animal Welfare Science
Verified
Journal Article
Closed access
RCRaisa Abreu Bragança Colocho
Raisa Abreu Bragança Colocho
ACAnna Cecília Trolesi Reis Borges Costa
Anna Cecília Trolesi Reis Borges Costa
BFBlenda Araujo Martins Ferreira
Blenda Araujo Martins Ferreira
AFAmanda Carvalho Rosado Ferreira
Amanda Carvalho Rosado Ferreira
DCDircéia Aparecida da Costa Custódio
Dircéia Aparecida da Costa Custódio
Elaine Maria Seles DornelesElaine Maria Seles Dorneles
Elaine Maria Seles Dorneles
The aim of this study was to analyze the demographic, clinical, and hematological aspects of the population in a dog shelter located in the municipality of Lavras, Brazil. All animals were microchipped and evaluated by veterinarians. Whole blood samples were obtained from 329 dogs in the months of July-August 2019 and from 310 dogs in the months of January-February 2020. Most of the dogs were of mixed breed, received anti-rabies and polyvalent vaccines (100%), were dewormed (100%), and were spayed/neutered (98.59%), with a predominance of adult (86.51%), short-hair (67.51%), normal body condition (65.57%), medium-size (62.57%), and female (62.36%). The main clinical alterations detected were enlarged lymph nodes (38.69%), skin lesions (31.50%), overweight (23.32%), obesity (6.07%), elevated temperature (17.05%), and ear secretion (15.72%). Regarding hematological alterations, thrombocytopenia (36.31%), leukopenia (15.92%), anemia with decreased hemoglobin values (10.60%), hematocrit (9.70%), and red blood cells (5.14%) were observed. Most of the shelter dogs were apparently healthy, but specific measures for nutritional, dermatological, otological and disease management should be implemented once the health changes are verified, as they impact the general state of the population and adoptions.

18 July 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
MSMaria de Fátima Santos
Maria de Fátima Santos
IMIris da Fátima Mariotto
Iris da Fátima Mariotto
IMIsabela Lopes Massitel
Isabela Lopes Massitel
FRFernando Marcos Rubim
Fernando Marcos Rubim
JAJoão Vitor Fernandes Cotrim de Almeida
João Vitor Fernandes Cotrim de Almeida
MFMARCOS FERRANTE
MARCOS FERRANTE
As fluoroquinolonas são drogas sintéticas que evoluíram ao longo do tempo, sendo formadas por um grupo de antibióticos desenvolvido a partir do ácido nalidíxico, contendo assim, quatro gerações com diferenças estruturais que alteram o espectro de atividade. As fluroquinolonas são utilizadas em todo o mundo no tratamento de infecções de origem bacteriana. Este estudo teve como objetivo reunir informações sobre o uso das fluoroquinolonas em cães e gatos domésticos. Para a realização desta revisão bibliográfica, foram coletados os dados do período de 2006 a 2019 na literatura disponível no Portal da Capes, no Google Acadêmico e em livros, utilizando-se os seguintes descritores: fluroquinolones in dogs e fluroquinolones in cats, também sendo empregadas estas palavras em português. A partir desta busca pode-se verificar que as fluroquinolonas são indicadas em terapias humanas e veterinárias, e possuem, atualmente, atividade antimicrobiana bastante satisfatória, boa disponibilidade através da via oral, boa difusão para os tecidos, meia-vida prolongada e toxicidade significativamente reduzida. A resistência a este antibiótico pode ser atribuída a fatores como: uso indiscriminado e abusivo, facilidade de acesso, uso errôneo em tratamentos não-infecciosos, entre outros fatores. São indicadas principalmente para cães e gatos com infecções bacterianas de organismos Gram-negativos, Gram-positivos e bactérias anaeróbias. Conclui-se que os antimicrobianos do grupo das quinolonas evoluíram ao longo do tempo, com a intenção de criar antimicrobianos eficazes, de ampla ação, mínimos efeitos adversos e preço acessível.

28 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
Kevellyn Silveira Gomes Martins
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
RMReiner Silveira de Moraes
Reiner Silveira de Moraes
PGPriscylla Tatiana Chalfun Guimaraes-Okamoto
Priscylla Tatiana Chalfun Guimaraes-Okamoto
MFMARCOS FERRANTE
MARCOS FERRANTE
Background/Objectives: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model to predict gentamicin therapeutic protocols for dogs with varying degrees of renal function impairment, considering the minimum inhibitory concentrations (MICs) of the infecting bacteria. Methods: The PBPK model was built using PK-Sim® software (OPEN SYSTEMS PHARMACOLOGY), based on pharmacokinetic data available in the literature and information on the physicochemical properties of the drug. Model evaluation included the calculation of the geometric mean fold error (GMFE), weighted and percentage residuals were calculated, as well as the following measures: AFE, AWRi, MWRi, MAWRi, APE%, MPE%, MAPE%, MdPE%, and MdAPE%. Therapeutic efficacy was assessed according to the Probability of Target Attainment (PTA), considering an MIC distribution of 0.25 to 8 μg/mL for different doses (2, 4, 6, 8, and 10 mg/kg) using the PK/PD indices Cmax/MIC ≥ 10, AUC/MIC ≥ 50, and AUC/MIC ≥ 110. To compare the pharmacokinetics of gentamicin between healthy dogs and those with decreased renal function, different GFR values corresponding to stages of renal impairment were used, as determined by clinical biomarkers (microalbuminuria, UPC ≥ 2, sCr ≥ 1.2 mg/dL, sCr ≥ 2.4 mg/dL, and sCr ≥ 5 mg/dL). The risk of toxicity was assessed according to AUC24h ≥ 700 mg·h/L and Cmin ≥ 0.5. Results: The model demonstrated good predictive performance, with a GMFE value of 1.13 meeting the double error criterion, and weighted residuals randomly distributed around 0 (p = 0.3792). Through the calculation of PTA, it was observed that efficacy varied according to the PK/PD index used, but values greater than 90% were obtained for MICs up to 4 μg/mL. The model allowed the estimation of protocols for each stage of renal impairment, considering the GFR of each group and the risk of nephrotoxicity, in association with the optimal dose to ensure therapeutic efficacy. Conclusions: These findings make it possible to propose a dose for the treatment of an infection, considering the MIC and the patient’s GFR stage, thereby reducing the risk of adverse effects without compromising treatment efficacy.

27 February 2026 in Semina: Ciências Agrárias
Verified
Journal Article
Open access
PDF file
Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
Kevellyn Silveira Gomes Martins
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
KVKarina Krauss Ferraz Vasconcelos
Karina Krauss Ferraz Vasconcelos
DDDiego Díaz
Diego Díaz
NWNelsa Widerhon
Nelsa Widerhon
This study used population pharmacokinetic (popPK) modeling to predict therapeutic efficacy and assess nephrotoxicity risk associated with gentamicin administration in dogs. The model was developed in Monolix 2024 R1 (Lixoft SAS, Simulations Plus Company) using plasma concentrationtime data obtained from the literature. Monte Carlo simulations were subsequently performed in Simulx 2024 (Lixoft SAS, Simulations Plus Company) for gentamicin doses of 2, 4, 6, and 8 mg kg-1 to evaluate therapeutic target attainment and exposure associated with nephrotoxicity risk. The model that best described the observed data was a two-compartment model with linear elimination. Predicted therapeutic efficacy was assessed using the Probability of Target Attainment (PTA) based on the PK/PD target fCmax/MIC ≥ 10 across a range of minimum inhibitory concentrations (MICs). Nephrotoxicity risk was evaluated according to the duration for which plasma gentamicin concentrations remained above the primary nephrotoxicity-risk threshold of 2 μg mL-1. The 8 mg kg-1 regimen achieved PTA values ≥ 90% for pathogens with MIC ≤ 2.0 μg mL-1 and represented the highest-performing simulated regimen among those evaluated. For this regimen, the mean time above the 2 μg mL-1 nephrotoxicity-risk threshold ranged from 4 to 8 hours. These findings support the use of gentamicin against pathogens with MICs ≤ 2 μg mL-1 when administered using extended dosing intervals. However, dose and interval adjustments may be required in critically ill patients. Overall, the popPK approach provides a useful framework for precision dosing, supporting improved predicted efficacy and safety across different dosing regimens.

1 January 2022 in Pubvet
Verified
Journal Article
Closed access
PDF file
COCintia Ferreira Antunes de Oliveira
Cintia Ferreira Antunes de Oliveira
ETEmanuely Ramos Tameirão
Emanuely Ramos Tameirão
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
LBLuciana de Castro Barcelos
Luciana de Castro Barcelos
LBLidiane da Silva Bastos
Lidiane da Silva Bastos
MFMarcos Ferrante
Marcos Ferrante
Para que os protocolos terapêuticos sejam corretamente instituídos é necessário entender corretamente como serão aplicados. A presente revisão bibliográfica tem como objetivo caracterizar as diferentes vias de administração usadas na Medicina Veterinária felina. Dessa forma, serão abordados diversos exemplos de fármacos utilizados por vias enterais e parenterais. Uma vez que essas particularidades são estudadas, é possível compreender de que maneira cada via atua, fator que aumenta consideravelmente a eficácia dos tratamentos. Em razão da administração de fármacos pelas vias incorretas, bem como da escolha terapêutica na maioria das vezes inapropriada para essa espécie, muitos gatos acabam se intoxicando. Em decorrência da sua deficiência de metabolização hepática e predisposição a desenvolver afecções renais, muitos pacientes têm prognóstico desfavorável e acabam vindo a óbito. Portanto, a fim de evitar possíveis intoxicações por vias de administração incorretas, e melhorar a escolha terapêutica, buscou-se elucidar os diferentes tipos de medicamentos utilizados na espécie felina e formas de administração que podem ser empregadas nesses animais.